MetaCap

LENZ Therapeutics (LENZ) vs Molecular Partners (MOLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Molecular Partners (MOLN) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 37.5% versus a loss of 90.0%. Over five years, MOLN leads with a -77.9% price change compared with -95.6% for LENZ. Molecular Partners is the larger company by market cap ($96.8 million vs $93.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LENZ-89.97%MOLN-37.50%
+33%-32%-96%
Nov 21, 20251 yearNov 20, 2026
LENZ-96.18%MOLN-75.84%
+220%+54%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LENZ versus MOLN key metrics
MetricLENZMOLN
Share price$2.97$2.53
Market cap$93.16M$96.80M
1-day change-11.23%-5.25%
YTD return-81.47%-42.07%
1-year return-89.97%-37.50%
5-year return-95.57%-77.87%
EPS (TTM)$-4.53$-1.68
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$19.09M—
Net income (latest FY)$-82.13M—
Gross margin97.81%—
Operating margin-477.46%—
Net margin-430.25%—
52-week high$32.13$5.36
52-week low$2.80$2.52
Distance from 52-week high-90.77%-52.89%
Analyst consensusnonestrong_buy
Avg. price target upside+400.17%+295.64%
Average volume892.30K1.63K
Shares outstanding31.42M38.34M
Employees40134
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MOLN has outperformed LENZ by 52.5 percentage points over the past year.

About LENZ Therapeutics

LENZ stock →

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

About Molecular Partners

MOLN stock →

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

LENZ vs MOLN FAQ

Which is bigger, LENZ Therapeutics or Molecular Partners?

Molecular Partners (MOLN) is larger, with a market capitalization of $96.80M compared with $93.16M for LENZ Therapeutics (LENZ).

Which stock has performed better over the past year, LENZ or MOLN?

MOLN returned -37.50% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.

Are LENZ Therapeutics and Molecular Partners in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons